Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. - Wikidata - wikimedia - TriplyDB

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

http://www.wikidata.org/entity/Q54500899

about

Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Medical treatment of renal cancer: new horizons Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells Trial Watch-Immunostimulation with cytokines in cancer therapy Immunotherapy for metastatic renal cell carcinoma.Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.Immunotherapy in genitourinary malignancies.Interferons: Success in anti-viral immunotherapy.Renal cell carcinoma: molecular biology and targeted therapy Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma.Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice BEZ235: When Promising Science Meets Clinical Reality Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.Bevacizumab: a review of its use in advanced cancer.The emerging quest for the optimal angiostatic combination therapy.Kidney cancer and 2014: is innovation really over?Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis.Suppression of mTOR pathway in solid tumors: lessons learned from clinical experience in renal cell carcinoma and neuroendocrine tumors and new perspectives.Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma.First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis.New advances in genitourinary cancer: evidence gathered in 2014.Emerging therapeutic approaches in renal cell carcinoma.Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions.Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents.Emerging therapeutics in refractory renal cell carcinoma.A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials.

P2860

Q26774515-AF2BDF81-4D9F-4DE6-A22C-20EE334B0420 Q28073174-B1241749-80E1-457D-A38B-6B14DE4EA378 Q28078154-216FCAC3-522B-4451-844D-33C60603ABA4 Q28078725-AFF98933-BC5F-4918-B840-3450F37A4330 Q30234458-E08F1E14-C05C-46D7-8F65-FA02A56ECA34 Q30249385-FD30CE64-74D7-4329-BE29-2A376E815376 Q33415842-4FD4E69B-1406-4A76-BBB8-008907E1DB8D Q33419097-15172860-2A5A-4425-95B8-A0BE0A6E3101 Q33593800-5735C695-DD8F-4B62-A8C9-3A3853974CB1 Q34276038-06F1E2C5-FFE1-4308-8894-B6C6EE80DC27 Q34513914-AE090C27-1976-468E-8096-6D87939212EF Q35144490-49E779C9-3B01-44A7-B757-FE2EB10A717B Q35504499-035F6E79-ECD1-49F5-AC63-D5670AD6DC34 Q35563828-EFD90066-8B27-4390-A647-2FE51A0E3B45 Q35920803-CB0FFFFC-B575-462D-80F3-F41AFC7D58E4 Q35948290-944FACEF-A16E-4BC3-8D71-5B29317762AD Q36051199-C1C08CC2-3D08-476E-9C8B-97AC80C00772 Q36310209-77F62D0E-8399-4B85-8B55-E1263717F466 Q36799900-53817A10-4E3C-4AE2-9CDF-AC51ED4899A2 Q37144518-0CBA99F7-C3BA-4796-B5EA-8F54FA2085BA Q37242369-47FB67B4-DC1C-44BB-9852-CB70803BACC6 Q37399308-FB8DBC0A-73F1-449A-B217-84A92BBD594C Q37562355-B34E3AAC-EBCF-434E-A47B-CCD10DA64E7E Q37602900-3138E3C9-F2AC-4B48-8661-FF1C124F10BD Q38260176-4FB422CD-90CB-4732-88D4-66F4E8E42C98 Q38268453-06263A55-92AF-4992-88BA-386C933FEBD5 Q38465870-30DC72DF-C1C9-4E2C-B340-77ADFA27723C Q38494344-5E25D8CC-DFDA-45E5-8825-024C7214B052 Q38527936-CAF7F480-1C21-456D-8513-D781EE4D924D Q38540687-A3E79EEE-1E37-4ABF-B56D-B4FF7D8CBE27 Q38550942-AFD71441-94E6-4FFB-BBF6-71D9CCA87DEF Q38557894-E874C6E7-8842-415E-99A5-ADEFD4A9BF93 Q38587958-31166795-E25F-4FCB-81D2-EDA9B073F55B Q38647604-C4D89D1E-A056-41BD-B708-863010D968EA Q38754614-2C8A31B7-F9BB-4406-9F4E-2E2B65661EF7 Q38762066-219AD22E-972E-48D5-89D4-4A095046737D Q38783324-494F91CD-BFF4-4F53-88A1-F44ED4740CAB Q38816892-D5E5AE29-7E85-477D-A607-0A8F1F97213B Q38865046-C373F626-32B6-4052-8096-BEBBFD95AE9B Q38882776-91E7DAED-8E93-4318-B508-1BE851686A64

P2860

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

http://www.wikidata.org/entity/Q54500899

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Randomized phase III trial of ...... ell carcinoma: INTORACT trial.

@en

Randomized phase III trial of ...... ell carcinoma: INTORACT trial.

@nl

type

label

Randomized phase III trial of ...... ell carcinoma: INTORACT trial.

@en

Randomized phase III trial of ...... ell carcinoma: INTORACT trial.

@nl

prefLabel

Randomized phase III trial of ...... ell carcinoma: INTORACT trial.

@en

Randomized phase III trial of ...... ell carcinoma: INTORACT trial.

@nl

P1433

Q54500899-F2BE954E-1D53-40D7-91D6-CF0DECF9F94E

P1476

Q54500899-42112199-8D60-466A-AECE-9A35DD1BBF68

P2093

Q54500899-3C6342B2-2B3A-48F6-A85D-8526461C43C4

Q54500899-4CD48281-80CF-4C9C-9819-77C6A6ACE1B2

Q54500899-88DA1DD0-6626-4740-952C-0467B55F3708

Q54500899-88E5C0DB-1E90-4F73-A5D9-CF74590F64C3

Q54500899-A89584A8-6ECE-4F14-A6C0-06F80AA1CB97

Q54500899-E988560C-214E-4120-B69C-B58DF0F9FCC5

P304

Q54500899-514D5D11-7E78-461B-BA34-D3FC4334312C

P31

Q54500899-5B50C940-9499-4278-970F-57F2454E2213

P356

Q54500899-94EF7EDD-6D95-4AA8-8F16-DA067C2BD771

P407

Q54500899-F99E6480-A9F2-4440-B787-73F80F55CC14

P433

Q54500899-D3EDC05B-6729-4D60-8015-0EFCB93C880A

P478

Q54500899-5615262C-1CCE-490C-B225-4944A16108C9

P50

Q54500899-730ADE70-0818-4B29-B3A8-B6F5C08295AA

P577

Q54500899-7A14ADA4-CF75-4723-9335-BFE02082595E

P698

Q54500899-EA914FAE-5F6C-4E9B-9B4D-F537CA7AB8BD

P921

Q54500899-8C685159-C251-4519-9D2C-B9DC1CF95997

Q54500899-9C33C00F-8284-4DAF-B97F-0EE79318902F

P356

JCO.2013.50.5305

P1433

Journal of Clinical Oncology

P1476

Randomized phase III trial of ...... ell carcinoma: INTORACT trial.

@en

P2093

Andreas G Niethammer

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Jill Clancy

http://www.w3.org/2001/XMLSchema#string

Joaquim Bellmunt

http://www.w3.org/2001/XMLSchema#string

Kongming Wang

http://www.w3.org/2001/XMLSchema#string

Subramanian Hariharan

http://www.w3.org/2001/XMLSchema#string

P304

752-759

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2013.50.5305

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Bernard Escudier

P577

2013-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24297945

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial